1 day ago · OSAKA, Japan, Jan 30, 2025 – Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) is pleased to announce that its novel investigational respiratory syncytial virus (RSV) oral antiviral candidate S-337395, which is being jointly developed with UBE Corporation (Head office: Minato-ku, Tokyo; President and …

1 day ago · Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load. The Japanese pharmaceutical’s candidate, S-337395, saw success in reducing the impact of the virus as part of a Phase II human challenge study, a type of ...

18 hours ago · In adults aged 60 years and older, the seasonal global incidence of RSV infection is 16.11 cases per 1000 people. 7 RSV can also severely impact the elderly, with an estimated 27.44% developing pneumonia and 24.48% requiring hospitalization 6. About Shionogi in Infectious Disease

17 hours ago · Shionogi’s respiratory syncytial virus (RSV) antiviral for adults has proven its ability to reduce viral load in a phase 2 trial. The study saw 114 healthy adults inoculated with the virus and ...

18 hours ago · Shionogi & Co., Ltd. announced that its novel investigational respiratory syncytial virus (RSV) oral antiviral candidate S-337395, which is being jointly developed with UBE Corporation (Head office: Minato-ku, Tokyo; President and Representative Director: Masato Izumihara; hereafter "UBE"), has achieved its primary endpoint in a Phase 2 clinical trial.

Oct 15, 2024 · S-337395 is an oral, novel anti-RSV investigational drug that targets the protein, essential for RSV replication, thereby inhibiting its proliferation. A dose-dependent reduction of RSV in the lungs was confirmed in non-clinical trials, and currently, a Phase 2 trial is underway to assess the efficacy and safety of S-337395.

S-217622 is made by a company called Shionogi. It is a type of antiviral drug called a protease inhibitor. It stops the virus that causes COVID-19 (SARS-CoV-2) from multiplying. This means there could be fewer viruses for the body to fight, and it may help participants get better faster.